Ping-i C. Hsu

Taitung, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

Real-world comparative outcomes of atorvastatin, rosuvastatin, and lovastatin-niacin fixed-dose combination in metabolic dysfunction-associated steatotic liver disease: hepatic, metabolic, and economic perspectives.

Real-world comparative outcomes of atorvastatin, rosuvastatin, and lovastatin-niacin fixed-dose combination in metabolic dysfunction-associated steatotic liver disease: hepatic, metabolic, and economic perspectives.

Journal: Diabetology & metabolic syndrome

Published: April 18, 2026

Optimising mono-antibiotic eradication regimen by potent acid inhibitor and bismuth: a potential solution to rising clarithromycin resistance in Helicobacter pylori.

Optimising mono-antibiotic eradication regimen by potent acid inhibitor and bismuth: a potential solution to rising clarithromycin resistance in Helicobacter pylori.

Journal: Gut

Published: February 16, 2026

Bismuth-Amoxicillin-Vonoprazan Triple, Amoxicillin-Vonoprazan Dual, and Clarithromycin-Based Triple Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Open-Label, Randomized Trial.

Bismuth-Amoxicillin-Vonoprazan Triple, Amoxicillin-Vonoprazan Dual, and Clarithromycin-Based Triple Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Open-Label, Randomized Trial.

Journal: Helicobacter

Published: February 02, 2026

Evolution of Amoxicillin-Based Mono-Antibiotic Regimens for Helicobacter pylori Eradication: From Ineffectiveness to Innovation-A Systematic Review.

Evolution of Amoxicillin-Based Mono-Antibiotic Regimens for Helicobacter pylori Eradication: From Ineffectiveness to Innovation-A Systematic Review.

Journal: Microorganisms

Published: December 29, 2025

Response to Zhao et al.

Response to Zhao et al.

Journal: The American journal of gastroenterology

Published: December 18, 2025

Sequential changes of antibiotic resistances of Helicobacter pylori in Taiwan from 2019 to 2024.

Sequential changes of antibiotic resistances of Helicobacter pylori in Taiwan from 2019 to 2024.

Journal: World journal of gastroenterology

Published: July 01, 2025

Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II.

Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II.

Journal: Gut

Published: June 02, 2025

Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review.

Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review.

Journal: Microorganisms

Published: January 22, 2025

Vonoprazan High-Dose Dual, Vonoprazan Triple, and Rabeprazole Reverse Hybrid Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter Randomized Trial.

Vonoprazan High-Dose Dual, Vonoprazan Triple, and Rabeprazole Reverse Hybrid Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter Randomized Trial.

Journal: The American journal of gastroenterology

Published: January 18, 2025

Future direction of Helicobacter pylori infection treatment.

Future direction of Helicobacter pylori infection treatment.

Journal: Lancet (London, England)

Published: January 07, 2025

Comparison of continuous versus on-demand proton pump inhibitor therapy in symptom control of patients with Barrett's esophagus.

Comparison of continuous versus on-demand proton pump inhibitor therapy in symptom control of patients with Barrett's esophagus.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: November 09, 2024

Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study.

Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study.

Journal: Oncology

Published: August 12, 2024

Showing 1-12 of 114

Last Updated: 09/26/2026